AMD – a glimpse into the futureJaheed Khan

Symptoms of AMD

Dry AMD

Wet AMD

Wet AMD scarring

Dry AMD OCT

OCT wet AMD

Treatments for Dry AMD

No medical treatment for dry type

Magnifying vision and good illumination help

IMT for end stage AMD

Focal laser for wet AMD

Photodynamic therapy

RPE Cell Translocation

VEGF

Anti –VEGF Rx

Anti-VEGF differences

Radiotherapy Rx for wet AMD

Future AMD Rx

Future AMD Rx

Future AMD Rx

Future AMD Rx

Future AMD Rx

Future AMD Rx

Future AMD RxDry AMD pipeline: most promising candidates

• Ciliary Neurotrophic Factor: Neuroprotective implant, phase II• Fenretinide: Decreases serum retinol, oral, phase II• OT-551: Anti-oxidant, anti inflammatory, topical, phase II• POT-4: Complement C3 inhibitor, phase II• Glatiramer Acetate: Immunomodulator, subcutaneous, phase II• Rheopheresis: Plasmapheresis, phase III

Future AMD RxWet AMD pipeline: most promising candidates • adPEDF.11: Gene therapy, intravitreal injection, phase I• AGN211745: siRNA, intravitreal injection, phase II• Zybrestat: vascular disrupting agent, topical, animal studies• Sirolimus: Multi-mechanism, Subconjunctival or intravitreal injection or oral, phase II• ATG003: nAChR antagonist, topical , phase II• Vatalanib: Tyrosine kinase inhibitor, oral, phase II• Pazopanib: Tyrosine kinase inhibitor, , topical , phase II• TG101095 / TG100801: Tyrosine kinase inhibitor, topical, phase II• AL-39324: Tyrosine kinase inhibitor, intravitreal injection, animal studies• AG013958: Tyrosine kinase inhibitor, subtenon injection, animal studies• JSM6427: integrin antagonist, intravitreal injection, phase I• PF-04523655 (REDD14NP) Wet AMD; phase I (Quark/Pfizer)

AMD – a glimpse into the future